抗胆碱能支气管扩张剂在慢性阻塞性肺疾病稳定期治疗中的应用进展  

Progress in Application of Anticholinergic Bronchodilators in Treatment of Stable Phase of Chronic Obstructive Pulmonary Disease

作　　者：欧阳张宁 高凌云[2] OUYANG Zhangning;GAO Lingyun(Department of Respiratory and Critical Care Medicine,Jiangyou Hospital Affiliated to North Sichuan Medical College/Jiangyou People′s Hospital,Jiangyou 621700,China;Department of Respiratory and Critical Care Medicine,Sichuan People′s Hospital,Chengdu 610000,China)

机构地区：[1]川北医学院附属江油医院江油市人民医院呼吸与危重症医学科,四川江油621700 [2]四川省人民医院呼吸与危重症医学科,成都610000

出　　处：《医学综述》2023年第15期3027-3031,共5页Medical Recapitulate

基　　金：四川省科技计划项目(2020YFS0409)。

摘　　要：慢性阻塞性肺疾病稳定期(sCOPD)治疗目的是为了缓解患者临床症状,预防急性加重发生。目前,抗胆碱能支气管扩张剂在sCOPD治疗中已有了一定的研究进展,其中长效抗胆碱能药物可有效缓解患者临床症状,改善肺功能,降低sCOPD急性加重的发生率。随着对COPD病理生理机制深入研究,新型的抗胆碱能药物正在不断涌现,如UmeclidiniumI、CHF5407等,这些药物疗效和安全性均在不断提升。未来随着纳米技术等的发展,相关研究将有更深入的进展,以更好地服务于sCOPD患者。The purpose treatment for stable chronic obstructive pulmonary disease(sCOPD)is to alleviate clinical symptoms and prevent acute exacerbation.At present,anticholinergic bronchiectasis has made some research progress in the treatment of sCOPD,among which long-acting anticholinergic drugs can effectively alleviate the clinical symptoms,improve lung function,and reduce the incidence of acute exacerbation of sCOPD of the patients.With in-depth research on the pathological and physiological mechanisms of COPD,new anticholinergic drugs are constantly emerging,such as UmecladiniumI,CHF5407,etc.,the efficacy and safety of which are constantly improving.In the future,with the development of nanotechnology etc.,there will be more in-depth progress in the related research,to better serve sCOPD patients.

关 键 词：慢性阻塞性肺疾病稳定期 抗胆碱能支气管扩张剂 纳米技术 

分 类 号：R563[医药卫生—呼吸系统]